|
1
|
Woodruff TK, Besecke LM, Groome N, Draper
LB, Schwartz NB and Weiss J: Inhibin A and inhibin B are inversely
correlated to follicle stimulating hormone, yet are discordant
during the follicular phase of the rat estrous cycle and inhibin A
is expressed in a sexually dimorphic manner. Endocrinology.
137:5463–5467. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ge J, Fan Y, Lu Y, Qi Y, Wang M and Liu Z:
Activin A increases arterial pressure in the hypothalamic
paraventricular nucleus in rats by angiotension II. Neuroreport.
27:683–688. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Matzuk MM, Kumar TR, Vassalli A,
Bickenbach JR, Roop DR, Jaenisch R and Bradley A: Functional
analysis of activins during mammalian development. Nature.
374:354–356. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hoda MA, Rozsas A, Lang E, Klikovits T,
Lohinai Z, Torok S, Berta J, Bendek M, Berger W, Hegedus B, et al:
High circulating activin A level is associated with tumor
progression and predicts poor prognosis in lung adenocarcinoma.
Oncotarget. 7:13388–13399. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Antsiferova M, Martin C, Huber M,
Feyerabend TB, Förster A, Hartmann K, Rodewald HR, Hohl D and
Werner S: Mast cells are dispensable for normal and
activin-promoted wound healing and skin carcinogenesis. J Immunol.
191:6147–6155. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Loomans HA and Andl CD: Intertwining of
activin A and TGFβ signaling: Dual roles in cancer progression and
cancer cell invasion. Cancers (Basel). 7:70–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Niu L, Cui X, Qi Y, Xie D, Wu Q, Chen X,
Ge J and Liu Z: Involvement of TGF-β1/Smad3 signaling in carbon
Tetrachloride-induced acute liver injury in mice. PLoS One.
11:e01560902016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miyazawa K, Shinozaki M, Hara T, Furuya T
and Miyazono K: Two major Smad pathways in TGF-beta superfamily
signaling. Genes Cells. 7:1191–1204. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vallet S, Mukherjee S, Vaghela N,
Hideshima T, Fulciniti M, Pozzi S, Santo L, Cirstea D, Patel K,
Sohani AR, et al: Activin A promotes multiple myeloma-induced
osteolysis and is a promising target for myeloma bone disease. Proc
Natl Acad Sci USA. 107:pp. 5124–5129. 2010; View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu HY, Wang YN, Ge JY, Li N, Cui XL and
Liu ZH: Localization and role of activin receptor-interacting
protein 1 in mouse brain. J Neuroendocrinol. 25:87–95. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yamakawa N, Tsuchida K and Sugino H: The
rasGAP-binding protein, Dok-1, mediates activin signaling via
serine/threonine kinase receptors. EMBO J. 21:1684–9164. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Duggal G, Heindryckx B, Warrier S, Taelman
J, Van der Jeught M, Deforce D, de Sousa Lopes S Chuva and De
Sutter P: Exogenous supplementation of Activin A enhances germ cell
differentiation of human embryonic stem cells. Mol Hum Reprod.
21:410–423. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Okuma Y, Saito K, O'Connor AE, Phillips
DJ, de Kretser DM and Hedger MP: Reciprocal regulation of activin A
and inhibin B by interleukin-1 (IL-1) and follicle-stimulating
hormone (FSH) in rat Sertoli cells in vitro. J Endocrinol.
185:99–110. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fang L, Wang YN, Cui XL, Fang SY, Ge JY,
Sun Y and Liu ZH: The role and mechanism of action of activin A in
neurite outgrowth of chicken embryonic dorsal root ganglia. J Cell
Sci. 125:1500–1507. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Walton KL, Makanji Y and Harrison CA: New
insights into the mechanisms of activin action and inhibition. Mol
Cell Endocrinol. 359:2–12. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ge J, Wang Y, Feng Y, Liu H, Cui X, Chen
F, Tai G and Liu Z: Direct effects of activin A on the activation
of mouse macrophage RAW264.7 cells. Cell Mol Immunol. 6:129–133.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li N, Cui X, Ge J, Li J, Niu L, Liu H, Qi
Y, Liu Z and Wang Y: Activin A inhibits activities of
lipopolysaccharide-activated macrophages via TLR4, not of TLR2.
Biochem Biophys Res Commun. 435:222–228. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Le Bras GF, Loomans HA, Taylor CJ, Revetta
FL and Andl CD: Activin A balance regulates epithelial invasiveness
and tumorigenesis. Lab Invest. 94:1134–1146. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu S, Qi Y, Niu LM, Xie DX, Cui XL and Liu
ZH: Activin A as a novel biomarker for colorectal adenocarcinoma in
humans. Eur Rev Med Pharmacol Sci. 19:4371–437. 2015.PubMed/NCBI
|
|
20
|
Gold E and Risbridger G: Activins and
activin antagonists in the prostate and prostate cancer. Mol Cell
Endocrinol. 359:107–112. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fujii Y, Kawakami S, Okada Y, Kageyama Y
and Kihara K: Regulation of prostate-specific antigen by activin A
in prostate cancer LNCaP cells. Am J Physiol Endocrinol Metab.
286:E927–E931. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Balanathan P, Williams ED, Wang H,
Pedersen JS, Horvath LG, Achen MG, Stacker SA and Risbridger GP:
Elevated level of inhibin-alpha subunit is pro-tumourigenic and
pro-metastatic and associated with extracapsular spread in advanced
prostate cancer. Br J Cancer. 100:1784–1793. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Garcia-Gomez A, Sanchez-Guijo F, Del
Cañizo MC, San Miguel JF and Garayoa M: Multiple myeloma
mesenchymal stromal cells: Contribution to myeloma bone disease and
therapeutics. World J Stem Cells. 6:322–343. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Terpos E, Kastritis E, Christoulas D,
Gkotzamanidou M, Eleutherakis-Papaiakovou E, Kanellias N,
Papatheodorou A and Dimopoulos MA: Circulating activin-A is
elevated in patients with advanced multiple myeloma and correlates
with extensive bone involvement and inferior survival; no
alterations post-lenalidomide and dexamethasone therapy. Ann Oncol.
23:2681–2686. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Prokhorova EA, Zamaraev AV, Kopeina GS,
Zhivotovsky B and Lavrik IN: Role of the nucleus in apoptosis:
Signaling and execution. Cell Mol Life Sci. 72:4593–4612. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Delgado Y, Morales-Cruz M, Hernández-Román
J, Martínez Y and Griebenow K: Chemical glycosylation of cytochrome
c improves physical and chemical protein stability. BMC Biochem.
15:162014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Peng X, Yu Z, Liang N, Chi X, Li X, Jiang
M, Fang J, Cui H, Lai W, Zhou Y and Zhou S: The mitochondrial and
death receptor pathways involved in the thymocytes apoptosis
induced by aflatoxin B1. Oncotarget. 7:12222–12234. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Roset R, Ortet L and Gil-Gomez G: Role of
Bcl-2 family members on apoptosis: What we have learned from
knock-out mice. Front Biosci. 12:4722–4730. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hassan M, Watari H, AbuAlmaaty A, Ohba Y
and Sakuragi N: Apoptosis and molecular targeting therapy in
cancer. Biomed Res Int. 2014:1508452014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mignard V, Lalier L, Paris F and Vallette
FM: Bioactive lipids and the control of Bax pro-apoptotic activity.
Cell Death Dis. 5:e12662014. View Article : Google Scholar : PubMed/NCBI
|
